PROFAR Statistics
Global clinical and logistics monitoring
ACTIVE
MHD-A DISPENSING
12,482 units
+3.2% from prev. cycle
MONITORING
PRM DETECTION RATE
0.84% incidence
-1.5% improvement
ACTION REQ
LOGISTICS ALERTS
14 critical
3 safety, 11 stock levels
OPTIMAL
COMPLIANCE SCORE
98.2% safety
Based on 5873M audit
Prescription & Stock Analysis
Units dispensed vs remaining stock
Incidence Breakdown
Distribution by type (%)
Interacciones
28%Errores Dosificación
45%Reacciones Adversas
12%Problemas Adherencia
15%Main Diagnosis Distribution by Category
Patient count by pathology groups
Total Patients by Category
3 patients
Respiratorias
1(33.3%)
Metabólicas
1(33.3%)
Cardiovasculares
1(33.3%)
PRM Detection Trends
Medication-Related Problems by severity
Adverse Drug Reactions12%
Dosage Errors45%
Interactions28%
Compliance Issues15%
Stock & Catalog Management
LOGISTICS MONITORING SERVICE
3 Deviations
| ID REFERENCE | MEDICATION DESCRIPTION | CURRENT STOCK | LOGISTICS STATUS | EXPIRY DATE | ACTION |
|---|---|---|---|---|---|
| MHDA-421 | Pembrolizumab Solution for infusion | 142 Units | STABLE | 12/11/2025 | |
| MHDA-089 | Adalimumab Subcutaneous injection | 8 Units | CRITICAL | 30/09/2024 | |
| MHDA-552 | Infliximab I.V. 100mg | 42 Units | DEVIATION | 01/12/2024 |